Skip to Main Content

Author Details

Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
2000
292
73
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37543465Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial.Eur Urol Oncol2024
34999586Patient Compliance in Assessing Electronic Patient-Reported Outcome Measures after Urologic Surgery.Urol Int2023
37488450Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.Br J Cancer2023
37642941MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.J Exp Med2023
37449970Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.Clin Cancer Res2023
37116492A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.Cancer Cell2023
37382622A self-supervised vision transformer to predict survival from histopathology in renal cell carcinoma.World J Urol2023
37209095Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.Cell Rep2023
37038006PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nat Cancer2023
37101151ecpc: an R-package for generic co-data models for high-dimensional prediction.BMC Bioinformatics2023
36585191Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory <i>In Silico</i> Analysis.Anticancer Res2023
36907692Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].Eur Urol2023
36765174Tumour-educated platelets for breast cancer detection: biological and technical insights.Br J Cancer2023
36865297Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.medRxiv2023
36864254Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.Nat Med2023
36631610γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.Nature2023
36525971IL-5-producing CD4<sup>+</sup> T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.Cancer Cell2023
36481539Prospective, Randomized Comparative Evaluation of a Novel Hands-On Endourology Training Curriculum.Urol Int2023
35939112Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.J Cancer Res Clin Oncol2023
35965206Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.Eur Urol2023
34477972Onset and burden of lower limb lymphedema after radical prostatectomy: a cross-sectional study.Support Care Cancer2022
35347010Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.Anticancer Res2022
35754340Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.Cancer Discov2022
35523804Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.NPJ Breast Cancer2022
36522513Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy.Discov Oncol2022
36465485<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.Oncoimmunology2022
36497449Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.Cancers (Basel)2022
36450752Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.Nat Commun2022
36239017Correction: Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.Clin Cancer Res2022
36035341Artificial intelligence for renal cancer: From imaging to histology and beyond.Asian J Urol2022
35992065Identifying mutant-specific multi-drug combinations using comparative network reconstruction.iScience2022
36323660MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.Nat Commun2022
36050473Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.Nature2022
35976907Deep learning can predict survival directly from histology in clear cell renal cell carcinoma.PLoS One2022
35274903Artificial intelligence to predict oncological outcome directly from hematoxylin and eosin-stained slides in urology.Minerva Urol Nephrol2022
35086954Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.Mol Cancer Ther2022
34965952Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.Clin Cancer Res2022
35197630Effective drug combinations in breast, colon and pancreatic cancer cells.Nature2022
32813094The comprehensive complication index (CCI): proposal of a new reporting standard for complications in major urological surgery.World J Urol2021
33576154Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.Mol Oncol2021
33568196Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.Genome Med2021
33706408Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer.BJU Int2021
33781339Peritoneal flap for lymphocele prophylaxis following robotic-assisted laparoscopic radical prostatectomy with pelvic lymph node dissection: study protocol and trial update for the randomized controlled PELYCAN study.Trials2021
33753731Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.NPJ Breast Cancer2021
34873056Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning.Proc Natl Acad Sci U S A2021
34987518The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.Front Immunol2021
34763270Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients.Breast2021
34438466Flexible co-data learning for high-dimensional prediction.Stat Med2021
34593530Ovarian Cancer-Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.Clin Cancer Res2021
34223192Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients.Nat Cancer2021
  • 1 - 50 of 292

Recommended Authors

Matthew Ung
Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth
Career Start Year 2013
Number of shared co-authors 0
Elana J Fertig
Johns Hopkins University School of Medicine
Career Start Year 2010
Number of shared co-authors 9
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 4
Stephen R Piccolo
Brigham Young University
Career Start Year 2008
Number of shared co-authors 6
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 7
James C Costello
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 7
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 2
Chao Cheng
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 3
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 15
Nathalie Pochet
Broad Institute of MIT and Harvard
Career Start Year 2004
Number of shared co-authors 4
Gabriela Alexe
Dana-Farber Cancer Institute
Career Start Year 2004
Number of shared co-authors 8
Adam A Margolin
Icahn School of Medicine
Career Start Year 2004
Number of shared co-authors 19
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2003
Number of shared co-authors 13
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 16
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 18
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 8
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 30
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 50
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 25
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 2
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 44
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 25
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 26
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 8
Aedin C Culhane
Dana-Farber Cancer Institute & Harvard School of Public Health
Career Start Year 1996
Number of shared co-authors 16
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 11
Kevin R Coombes
Medical College of Georgia
Career Start Year 1990
Number of shared co-authors 10
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 9
Pablo Tamayo
University of California San Diego
Career Start Year 1988
Number of shared co-authors 11
Paul C Boutros
University of California los angeles
Career Start Year 1970
Number of shared co-authors 100

Collaborators

Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 37
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 30
Laura J Van't Veer
University of California San Francisco
Co-authored papers 23
David J Adams
Wellcome Sanger Institute
Co-authored papers 19
Emile E Voest
The Netherlands Cancer Institute
Co-authored papers 14
Jeroen de Ridder
Center for Molecular Medicine, University Medical Center Utrecht
Co-authored papers 14
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 14
Sander Canisius
The Netherlands Cancer Institute
Co-authored papers 13
Magali Michaut
The Netherlands Cancer Institute
Co-authored papers 13
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Co-authored papers 13
Theo A Knijnenburg
Allen Institute for Cell Science
Co-authored papers 13
Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers 10
Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 9
Michiel S van der Heijden
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Co-authored papers 9
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 9
Edwin Cuppen
Hartwig Medical Foundation
Co-authored papers 8
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 7
Bas van Steensel
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 6
Oscar Krijgsman
The Netherlands Cancer Institute
Co-authored papers 6
Michael R Stratton
Wellcome Sanger Institute
Co-authored papers 6
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 5
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Co-authored papers 5
Connie R Jimenez
Co-authored papers 4
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 4
Sake van Wageningen
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 4
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 4
Ilya Shmulevich
Institute for Systems Biology
Co-authored papers 4
David A Largaespada
University of Minnesota
Co-authored papers 4
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 3
Release 1.2